1.
Carmody LC, Germain AR, VerPlank L, et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen. 2012;17(9):1204-10. doi:10.1177/1087057112458317.
1.
Cherniack AD, Shen H, Walter V, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31(3):411-423. doi:10.1016/j.ccell.2017.02.010.
1.
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007.
1.
Li J, Choi PS, Chaffer CL, et al. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018;7. doi:10.7554/eLife.37184.
1.
Puram SV, Tirosh I, Parikh AS, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017;171(7):1611-1624.e24. doi:10.1016/j.cell.2017.10.044.
1.
Meder L, König K, Dietlein F, et al. LIN28B enhanced tumorigenesis in an autochthonous KRAS-driven lung carcinoma mouse model. Oncogene. 2018;37(20):2746-2756. doi:10.1038/s41388-018-0158-7.
1.
Campbell JD, Yau C, Bowlby R, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018;23(1):194-212.e6. doi:10.1016/j.celrep.2018.03.063.
1.
Hagerstrand D, Tong A, Schumacher SE, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57. doi:10.1158/2159-8290.CD-12-0592.
1.
Wang J, Mikse O, Liao RG, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34(17):2167-77. doi:10.1038/onc.2014.161.
1.
Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171-84. doi:10.1016/j.cell.2014.06.004.